Share
156 Posts.
lightbulb Created with Sketch. 100
clock Created with Sketch.
17/06/16
09:56
Share
Merck-Bristol showdown awaits as Keytruda scores in 1st line NSCLC
Merck ($MRK) has chalked up a key win in a new trial for its marketed checkpoint inhibitor Keytruda after it bested chemotherapy and improved overall survival in certain lung cancer patients—but the company now awaits data from its fierce rival Bristol-Myers Squibb’s ($BMY) own first-line trial in Q3.
So good were the apparent data from Merck--which have not yet been shared in detail by the company--that the Data Monitoring Committee has recommended that the trial be stopped, and that those patients receiving chemotherapy in the Keynote-024 study be offered the opportunity to use Merck’s drug.
The trial was assessing Keytruda in patients as a first-line treatment in non-small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-L1 (tumor proportion score of 50% or more).
Expand
.. and the wait for Cavatak/Keytruda STORM Part B results continues.